{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:40:09Z","timestamp":1784202009106,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.dsx.2019.07.032","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T10:45:18Z","timestamp":1563014718000},"page":"2641-2646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study)"],"prefix":"10.1016","volume":"13","author":[{"given":"Maher BM.","family":"Boraie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser A.","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Othman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2019.07.032_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13186","article-title":"The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment","volume":"37","author":"Kandeel","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.dsx.2019.07.032_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"IR in chronic HCV: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl.1","key":"10.1016\/j.dsx.2019.07.032_bib3","first-page":"13","article-title":"Impact of hepatitis C virus therapy on metabolism and public health","volume":"37","author":"Shiffman","year":"2017","journal-title":"Liver Int. 2008"},{"issue":"3","key":"10.1016\/j.dsx.2019.07.032_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3748\/wjg.v18.i3.212","article-title":"Hepatitis C virus induced IR impairs response to anti-viral therapy","volume":"18","author":"El-Zayadi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dsx.2019.07.032_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.dld.2015.01.157","article-title":"Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic HCV. Results of a retrospective long-term controlled cohort study","volume":"47","author":"Coppo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dsx.2019.07.032_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dld.2015.10.016","article-title":"Treatment of T2DM mellitus by viral eradication in chronic HCV: myth or reality?","volume":"48","author":"Vannia","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"34","key":"10.1016\/j.dsx.2019.07.032_bib7","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dsx.2019.07.032_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: IR and beta-cell function from plasma fasting glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2019.07.032_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the esophagus for bleeding esophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"issue":"9","key":"10.1016\/j.dsx.2019.07.032_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4254\/wjh.v10.i9.549","article-title":"Challenge of hepatitis C in Egypt and hepatitis B in Mauritania","volume":"10","author":"Raad","year":"2018","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.dsx.2019.07.032_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0973-6247.126683","article-title":"Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays","volume":"8","author":"Gupta","year":"2014","journal-title":"Asian J Transfus Sci"},{"key":"10.1016\/j.dsx.2019.07.032_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4239\/wjd.v5.i5.586","article-title":"Hepatitis Cvirus infection and type 1 and T2DM mellitus","volume":"5","author":"Antonelli","year":"2014","journal-title":"World J Diabetes"},{"key":"10.1016\/j.dsx.2019.07.032_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10620-015-3907-2","article-title":"Current concepts in diabetes mellitus and chronic liver disease: clinical outcomes, hepatitis C virus association, and therapy","volume":"61","author":"Garc\u0131a-Compean","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dsx.2019.07.032_bib14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/gut.2010.228262","article-title":"IR and hepatitis C: an evolving story","volume":"60","author":"Eslam","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2019.07.032_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4239\/wjd.v1.i2.36","article-title":"Surrogate markers of insulin resistance: a review","volume":"1","author":"Singh","year":"2010","journal-title":"World J Diabetes"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.dsx.2019.07.032_bib16","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc17-S005","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.07.032_bib17","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.dsx.2019.07.032_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.04.023","article-title":"Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4","volume":"63","author":"Doss","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.dsx.2019.07.032_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13165","article-title":"Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post- transplant hepatitis C recurrence and severe fibrosis and cirrhosis: a prospective study","volume":"32","author":"Lionetti","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.dsx.2019.07.032_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","article-title":"Safety and efficacy of daclatasvir\/sofosbuvir in HCV genotype 1-mono-infected patients","volume":"66","author":"Pol","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.dsx.2019.07.032_bib21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jmv.24954","article-title":"Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents","volume":"90","author":"Ciancio","year":"2018","journal-title":"J\u00a0Med Virol"},{"issue":"9","key":"10.1016\/j.dsx.2019.07.032_bib22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care Sep."},{"key":"10.1016\/j.dsx.2019.07.032_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cmi.2016.09.021","article-title":"HCV and diabetes: towards a \u2018sustained\u2019 glycaemic improvement after treatment with DAAs?","volume":"23","author":"Fabrizio","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dsx.2019.07.032_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cmi.2015.12.030","article-title":"Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents","volume":"22","author":"Pavone","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dsx.2019.07.032_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/infdis\/jix517","article-title":"No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV","volume":"217","author":"Chaudhury","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.dsx.2019.07.032_bib26","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1111\/j.1572-0241.2008.02002.x","article-title":"Incidence of T2DM mellitus and glucose abnormalities in patients with chronic HCV infection by response to treatment: results of a cohort study","volume":"103","author":"Giordanino","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dsx.2019.07.032_bib27","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/jgh.14067","article-title":"HCV clearance by direct-acting antiviral treatment and impact on insulin resistance in chronic hepatitis C","volume":"33","author":"Adinolfi","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.dsx.2019.07.032_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kjms.2017.07.003","article-title":"The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents","volume":"33","author":"Huang","year":"2017","journal-title":"Kaohsiung J Med Sci"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140211930431X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140211930431X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:10:24Z","timestamp":1761729024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187140211930431X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S187140211930431X"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2019.07.032","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study)","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2019.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}